We’re committed to reinventing research and making healthcare integrate seamlessly into real patients’ real lives. We provide the end-to-end drug development services to make it happen. We take a data-driven approach to site selection at BBMCT, evaluating potential sites based on their access to the patient population, research infrastructure, past enrollment performance on similar studies, demonstrated ability to provide patient data in a timely fashion, and any potential competing clinical studies at the same site. Once evaluated, we only contact sites that are most likely to be interested in study participation and capable of meaningfully contributing to enrollment, saving you both time and money.
“If you set your goals ridiculously high and it’s a failure, you will fail above everyone else’s success.”
We support the phase II-III clinical development of niche treatments, blockbuster drugs, and biosimilars that help save lives. Clinical research and development are complex. Finding the right partner shouldn’t be. We work hand-in-hand with our sponsors to develop strategic, flexible approaches that leverage Clinical Informatics, state-of-the-art technologies, and our global reach to maximize safety and efficiency and make data-driven decisions for every study. We work with Principal Investigators and site staff to accurately project potential enrollment and optimize prescreening strategies, liaise with other departments to ensure data quality is maintained, and engage with non-participating physicians to generate interest in referring patients for your study.
The current drug development research paradigm is flawed in that it fails to include a diverse and representative patient population. A new approach that begins with a patient-centric mindset, coupled with the use of mobile technology and connected health platforms, will enable research to become less reliant on site-based visits and bring equal access to new investigational therapies for all patients, regardless of geography, ethnicity, sex, or gender.
Optimizing studies to reduce risk and save money.
Today, drug developers face an increasingly complex and evolving landscape. Regulatory agencies are demanding smarter, more efficient risk-based methodologies to improve data quality. In addition, the increasing cost of research and adoption of EDC technologies that provide real-time access to data have forced the industry to look at optimized methods of conducting clinical studies. By employing a Risk-Based-Monitoring (RBM) approach, we can holistically evaluate each individual study and determine the right organizational structure to support both central and on-site monitoring and see data trends in real-time.
Today’s drug development landscape is more complex than ever. That’s why we’ve made our approach to solving your challenges more simplified than ever. All the research expertise and all the data in the world won’t mean anything if they’re not being used to build strategies that work for real people in the real world.
Every day we’re pushing ourselves to become the catalyst that transforms our industry from patient-considerate, to truly human-centric. While we use expertise and data to answer your scientific questions, we use empathy and compassion to move us towards a happier, healthier world.